Your browser doesn't support javascript.
loading
Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase.
van de Munckhof, Anita; Lindgren, Erik; Kleinig, Timothy J; Field, Thalia S; Cordonnier, Charlotte; Krzywicka, Katarzyna; Poli, Sven; Sánchez van Kammen, Mayte; Borhani-Haghighi, Afshin; Lemmens, Robin; Scutelnic, Adrian; Ciccone, Alfonso; Gattringer, Thomas; Wittstock, Matthias; Dizonno, Vanessa; Devroye, Annemie; Elkady, Ahmed; Günther, Albrecht; Cervera, Alvaro; Mengel, Annerose; Chew, Beng Lim Alvin; Buck, Brian; Zanferrari, Carla; Garcia-Esperon, Carlos; Jacobi, Christian; Soriano, Cristina; Michalski, Dominik; Zamani, Zohreh; Blacquiere, Dylan; Johansson, Elias; Cuadrado-Godia, Elisa; Vuillier, Fabrice; Bode, Felix J; Caparros, François; Maier, Frank; Tsivgoulis, Georgios; Katzberg, Hans D; Duan, Jiangang; Burrow, Jim; Pelz, Johann; Mbroh, Joshua; Oen, Joyce; Schouten, Judith; Zimmermann, Julian; Ng, Karl; Garambois, Katia; Petruzzellis, Marco; Carvalho Dias, Mariana; Ghiasian, Masoud; Romoli, Michele.
Afiliación
  • van de Munckhof A; Department of Neurology (A.v.d.M., K.K., M.S.v.K., J.M.C.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
  • Lindgren E; Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden (E.L., K.J., T.T.).
  • Kleinig TJ; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden (E.L., K.J., T.T.).
  • Field TS; Department of Neurology, Royal Adelaide Hospital, Adelaide, Australia (T.J.K.).
  • Cordonnier C; Division of Neurology, Vancouver Stroke Program, University of British Columbia, Vancouver, Canada (T.S.F., V.D.).
  • Krzywicka K; University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, France (C.C., F.C.).
  • Poli S; Department of Neurology (A.v.d.M., K.K., M.S.v.K., J.M.C.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
  • Sánchez van Kammen M; Department of Neurology and Stroke, University Hospital Tuebingen (S.P., A.M., J.M.), Eberhard-Karls University, Germany.
  • Borhani-Haghighi A; Hertie Institute for Clinical Brain Research (S.P., J.M.), Eberhard-Karls University, Germany.
  • Lemmens R; Department of Neurology (A.v.d.M., K.K., M.S.v.K., J.M.C.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
  • Scutelnic A; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Iran (A.B.-H.).
  • Ciccone A; Department of Neurology, University Hospitals Leuven, Belgium (R.L., A.D.).
  • Gattringer T; Department of Neurology (A.S., M.R.H., M.A.), Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Wittstock M; Department of Neurology, Carlo Poma Hospital, Azienda Socio Sanitaria Territoriale di Mantova, Mantua, Italy (A. Ciccone).
  • Dizonno V; Department of Neurology, Medical University of Graz, Austria (T.G.).
  • Devroye A; Department of Neurology, University Hospital Rostock, Germany (M. Wittstock).
  • Elkady A; Division of Neurology, Vancouver Stroke Program, University of British Columbia, Vancouver, Canada (T.S.F., V.D.).
  • Günther A; Department of Neurology, University Hospitals Leuven, Belgium (R.L., A.D.).
  • Cervera A; Department of Neurology, Saudi German Hospital, Jeddah, Saudi Arabia (A.E.).
  • Mengel A; Department of Neurology, Jena University Hospital, Germany (A.G.).
  • Chew BLA; Royal Darwin Hospital, Darwin, Northern Territory, Australia (A. Cervera).
  • Buck B; Department of Neurology and Stroke, University Hospital Tuebingen (S.P., A.M., J.M.), Eberhard-Karls University, Germany.
  • Zanferrari C; Department of Neurology, John Hunter Hospital, Newcastle, Australia (B.L.A.C., C.G.-E.).
  • Garcia-Esperon C; Division of Neurology, University of Alberta Hospital, Edmonton, Canada (B.B.).
  • Jacobi C; Department of Neurology, Azienda Ospedaliera di Melegnano e della Martesana, Italy (C.Z.).
  • Soriano C; Department of Neurology, John Hunter Hospital, Newcastle, Australia (B.L.A.C., C.G.-E.).
  • Michalski D; Department of Neurology, Krankenhaus Nordwest, Frankfurt am Main, Germany (C.J.).
  • Zamani Z; Department of Neurology, Hospital General de Castellón, Castelló, Spain (C.S.).
  • Blacquiere D; Department of Neurology, Leipzig University Hospital, Germany (D.M., J. Pelz).
  • Johansson E; Department of Neurology, Firoozabadi Hospital (Z.Z.), Firoozgar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran.
  • Cuadrado-Godia E; Division of Neurology, The Ottawa Hospital, Canada (D.B.).
  • Vuillier F; Department Clinical Science, Wallenberg Center for Molecular Medicine (WCMM), Umeå University, Sweden (E.J.).
  • Bode FJ; Department of Neurology, University Hospital del Mar, Barcelona, Spain (E.C.-G.).
  • Caparros F; Stroke Unit, University Hospital of Besancon, France (F.V.).
  • Maier F; Department of Neurology, Universitätsklinikum Bonn, Germany (F.J.B., J.Z.).
  • Tsivgoulis G; University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, France (C.C., F.C.).
  • Katzberg HD; Department of Neurology, Caritas Hospital Saarbrücken, Germany (F.M.).
  • Duan J; Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Greece (G.T.).
  • Burrow J; Department of Neuromuscular Medicine, Toronto General Hospital, Canada (H.D.K.).
  • Pelz J; Department of Neurology and Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China (J.D.).
  • Mbroh J; Department of Neurology, Royal Darwin Hospital, Tiwi, Australia (J.B.).
  • Oen J; Department of Neurology, Leipzig University Hospital, Germany (D.M., J. Pelz).
  • Schouten J; Department of Neurology and Stroke, University Hospital Tuebingen (S.P., A.M., J.M.), Eberhard-Karls University, Germany.
  • Zimmermann J; Hertie Institute for Clinical Brain Research (S.P., J.M.), Eberhard-Karls University, Germany.
  • Ng K; Department of Neurology, Antonius Ziekenhuis, Sneek, the Netherlands (J.O.).
  • Garambois K; Department of Neurology, Rijnstate Hospital Arnhem, the Netherlands (J.S.).
  • Petruzzellis M; Department of Neurology, Universitätsklinikum Bonn, Germany (F.J.B., J.Z.).
  • Carvalho Dias M; Department of Neurology, Royal North Shore Hospital, Sydney, Australia (K.N., M. Wronski, S.C.).
  • Ghiasian M; Department of Neurology, CHU Grenoble Alpes, France (K.G., P.C.).
  • Romoli M; Department of Neurology, AOU Consorziale Policlinico di Bari, Italy (M.P.).
Stroke ; 53(10): 3206-3210, 2022 10.
Article en En | MEDLINE | ID: mdl-36082668
BACKGROUND: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. METHODS: We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022. VITT diagnosis was classified based on the Pavord criteria. Outcomes were mortality, functional independence (modified Rankin Scale score 0-2), VITT relapse, new thrombosis, and bleeding events (all after discharge from initial hospitalization). RESULTS: Of 107 CVT-VITT cases, 43 (40%) died during initial hospitalization. Of the remaining 64 patients, follow-up data were available for 60 (94%) patients (37 definite VITT, 9 probable VITT, and 14 possible VITT). Median age was 40 years and 45/60 (75%) patients were women. Median follow-up time was 150 days (interquartile range, 94-194). Two patients died during follow-up (3% [95% CI, 1%-11%). Functional independence was achieved by 53/60 (88% [95% CI, 78%-94%]) patients. No new venous or arterial thrombotic events were reported. One patient developed a major bleeding during follow-up (fatal intracerebral bleed). CONCLUSIONS: In contrast to the high mortality of CVT-VITT in the acute phase, mortality among patients who survived the initial hospitalization was low, new thrombotic events did not occur, and bleeding events were rare. Approximately 9 out of 10 CVT-VITT patients who survived the acute phase were functionally independent at follow-up.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / Trombosis / Vacunas / Trombosis de la Vena / Trombosis Intracraneal / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Stroke Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / Trombosis / Vacunas / Trombosis de la Vena / Trombosis Intracraneal / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Stroke Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos